BeOne Medicines AG (HKG:6160)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
228.00
+0.20 (0.09%)
Aug 21, 2026, 4:08 PM HKT

BeOne Medicines AG Stock Forecast

Stock Price Forecast

According to 17 analysts polled by S&P Global, BeOne Medicines AG stock has a consensus rating of "Strong Buy" and an average price target of $264.41. The average 1-year stock price forecast is 15.97% higher than the current stock price, while the lowest is $225.90 (-0.92%) and the highest is $321.57 (+41.04%).

Price Target: $264.41 (+15.97%)
Analyst Consensus: Strong Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$225.90$264.41$264.86$321.57
Change-0.92%+15.97%+16.17%+41.04%

Analyst Ratings

The average analyst rating for BeOne Medicines AG stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart
RatingMar '26Apr '26May '26Jun '26Jul '26Aug '26
Strong Buy141414131314
Buy333333
Hold000000
Sell000000
Strong Sell000000
Total171717161617

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Unknown Analyst
Daiwa
No rating
Daiwa
Buy
Maintains
$270.00
BuyMaintains$270.00+18.42%Aug 12, 2026
Unknown Analyst
CICC
No rating
CICC
Buy
Maintains
$266.00
BuyMaintains$266.00+16.67%Aug 11, 2026
Unknown Analyst
UBS
No rating
UBS
Buy
Maintains
$280.20
BuyMaintains$280.20+22.89%Aug 10, 2026
Unknown Analyst
BOCOM International Holdings Company
No rating
BOCOM International Holdings Company
Buy
Maintains
$276.00
BuyMaintains$276.00+21.05%Aug 9, 2026
Unknown Analyst
CLSA
No rating
CLSA
Buy
Maintains
$321.70
BuyMaintains$321.70+41.10%Aug 7, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
6.75B
from 5.34B
Increased by 26.42%
Revenue Next Year
7.71B
from 6.75B
Increased by 14.09%
EPS This Year
0.59
from 0.19
Increased by 213.02%
EPS Next Year
0.85
from 0.59
Increased by 43.64%
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
1.18B1.42B2.46B3.81B5.34B6.75B
Revenue Growth
280.83%20.37%73.65%54.97%40.23%26.42%
Gross Profit
1.01B1.13B2.08B3.22B4.67B5.97B
Gross Margin
85.98%79.77%84.55%84.41%87.49%88.40%
Operating Income
-1.44B-1.79B-1.21B-568.20M447.14M1.07B
Net Income
-1.46B-2.00B-881.71M-644.79M286.93M865.18M
EPS
----0.190.59
EPS Growth
-----213.02%
Forward PE
-----48.90
Free Cash Flow
-1.20B-943.69M-1.27B-370.91M655.53M823.09M
No. Analysts
-----29
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High6.9B
Avg6.8B
Low6.7B

Revenue Growth

Revenue Growth202620272028
High
28.3%
Avg
26.4%
Low
24.8%

EPS Forecast

EPS202620272028
High0.81
Avg0.59
Low0.42

EPS Growth

EPS Growth202620272028
High
327.9%
Avg
213.0%
Low
121.1%